Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Dreyfus

Showing results (281-290 of 304) with videos related to

Pageof 31
Sort By:
Leukemia Research|January 15, 2008
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomideC Kelaidi, S Park, S Brechignac, et al.
Leukemia Research|July 22, 2008
Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromesJ Tamburini, C Elie, S Park, et al.
Leukemia & Lymphoma|July 16, 2005
Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapyX Thomas, Qh Le, S de Botton, et al.
Leukemia|February 2, 2013
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agentsC Kelaidi, S Park, R Sapena, et al.
Leukemia|June 23, 2006
Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotypeV Bardet, L D Costa, C Elie, et al.
Leukemia|April 18, 2002
Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective studyF Lefrère, A Delmer, F Suzan, et al.
Leukemia|December 7, 2011
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemiaL Willems, N Chapuis, A Puissant, et al.
Leukemia|January 20, 2009
Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 casesR Itzykson, S Ayari, D Vassilief, et al.
Leukemia|August 18, 1999
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial)X Thomas, P Fenaux, H Dombret, et al.
Leukemia|January 17, 2013
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapseS Park, N Chapuis, F Saint Marcoux, et al.
Pageof 31

Showing results (281-290 of 304) with videos related to

Sort By:
Pageof 31
Leukemia Research|January 15, 2008
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomideC Kelaidi, S Park, S Brechignac, et al.
Leukemia Research|July 22, 2008
Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromesJ Tamburini, C Elie, S Park, et al.
Leukemia & Lymphoma|July 16, 2005
Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapyX Thomas, Qh Le, S de Botton, et al.
Leukemia|February 2, 2013
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agentsC Kelaidi, S Park, R Sapena, et al.
Leukemia|June 23, 2006
Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotypeV Bardet, L D Costa, C Elie, et al.
Leukemia|April 18, 2002
Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective studyF Lefrère, A Delmer, F Suzan, et al.
Leukemia|December 7, 2011
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemiaL Willems, N Chapuis, A Puissant, et al.
Leukemia|January 20, 2009
Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 casesR Itzykson, S Ayari, D Vassilief, et al.
Leukemia|August 18, 1999
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial)X Thomas, P Fenaux, H Dombret, et al.
Leukemia|January 17, 2013
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapseS Park, N Chapuis, F Saint Marcoux, et al.
Pageof 31